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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide
with an extremely poor prognosis. The classification of HCC based on the molecular signature is
not well-established.
Results: In the present study, we reported HCC signature genes based on the JNK1 activation
status in 31 HCC specimens relative to the matched distal noncancerous liver tissue from 31
patients. The HCCs with high JNK1 (H-JNK1) and low JNK1 (L-JNK1) were sub-grouped. Two
different signature gene sets for both H-JNK1 and L-JNK1 HCC were identified through gene
expression profiling. A striking overlap of signature genes was observed between the H-JNK1 HCC
and the hepatoblastoma or hepatoblastoma-type HCC. Many established biomarkers for hepatic
progenitor cells were over-expressed in H-JNK1 HCC, including AFP, TACSTD1, KRT19, KRT7,
THY1, and PROM1. In addition, the majority of the most up-regulated genes were those associated
with metastasis and earlier recurrence, whereas the genes for normal liver function were
substantially down-regulated in H-JNK1 HCC tissue. A Kaplan-Meier plot demonstrated that the
survival of the patients with H-JNK1 HCC was severely impaired.
Conclusion:  Accordingly, we believe that the H-JNK1 HCC may originate from hepatic
progenitor cells and is associated with poorer prognosis. The status of JNK1 activation in HCC
tissue, thus, might be a new biomarker for HCC prognosis and therapeutic targeting.
Background
Hepatocellular carcinoma (HCC) has plagued popula-
tions in Far East Asia, South Asia and Sub-Saharan Africa
for several decades where the prevalence of hepatitis B
viral (HBV) infection and aflatoxin exposure is high[1,2].
A sharp increase in HCC incidence in North America,
Western Europe and Japan has been noted in recent years
due to hepatitis C viral (HCV) infection, alcohol abuse
and non-alcoholic fatty liver disease [3-6]. HCC is the
fourth most common neoplasm and the third most com-
mon cause of cancer-related death worldwide. Age-
adjusted HCC incidence rates vary from 2 per 100,000
population in North America to 80 per 100,000 popula-
tion in China. Since most HCC patients are diagnosed
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when the tumors are in an advanced stage and the major-
ity of HCCs develop in the context of chronic liver cirrho-
sis, curative therapy is not available yet[7,8]. The overall 5-
year survival rate is lower than 5% [4]. Accordingly, a new
understanding of the molecular mechanisms controlling
the development and progression of HCC is urgently
needed for the efficient treatment of this deadly disease.
A major goal in current HCC research is to define gene sig-
natures that drive initiation, maintenance and progres-
sion of the malignant tumors, which is anticipated to be
helpful in classifying tumor stages and predicting prog-
nostic outcomes, such as metastasis, patient survival rate
and recurrence of the tumors after resection. It is also
highly desirable to use the gene signature to design tar-
geted therapies or the so-called personalized medicine [1].
However, amid this euphoria, the HCC signature genes
identified thus far vary considerably, depending on a
number of etiological and pathological features, includ-
ing viral infection, inflammation, cirrhosis, necrosis,
fibrosis, vascular invasion, tumor cell origination, and
environmental exposure. The situation is further compli-
cated by the byzantine complexity of algorithms for data
analysis and the use of different platforms for gene profil-
ing [9-12]. These factors might explain why so many
reports concerning HCC signature genes have resulted in
therapeutic dead ends.
Accumulating evidence suggests that activation of the pro-
tein kinases provides growth advantage to cells during
malignant transformation and tumorigenesis. Recently,
we[13,14] and Hui et al.[15] simultaneously demon-
strated critical role of JNK1 activation in the pathogenesis
of human HCC and/or a mouse model of chemical carcin-
ogen-induced HCC. Both studies observed overactivation
of JNK1 in about 55% and 56% human HCC relative to
the noncancerous liver tissue, respectively[13,15]. We
have shown an association between JNK1 activation and
overexpression of the genes for cell growth, histone meth-
ylation, and the downregulation of the genes for cell dif-
ferentiation, antioxidant defense and drug or lipid
metabolism[13]. By re-analyzing and comparing our gene
profiling data with the signature genes for HCC with a
poor prognosis and hepatoblastoma (HB) reported
recently[9,16], we found a striking overlap of the gene
expression pattern in high JNK1 (H-JNK1) HCC tissue
with the signature genes for HCC with a poor prognosis
and HB, respectively. Assessment of the patient survival
data indicates that the overall survival of the patients with
H-JNK1 HCC is substantially impaired. JNK1, rather than
JNK2, has been implicated in development of steatohepa-
titis[17,18] and carcinogen-induced mouse HCC[19]. It is
very likely, thus, that JNK1 is a critical contributor to the
progression of human HCC, which can serve as a poten-
tial target for new therapies.
Results
Gene profiling between HCC and the noncancerous liver 
tissue
HCC samples along with the case-matched distal noncan-
cerous liver tissue (ANC) were collected from 31 patients
(Table 1) during year 2005 and 2006 and gene profiling
using Affymetrix HG-U133 plus 2 microarrays was per-
formed as reported previously[13]. The data were re-nor-
malized using the GCRMA method and FDR correction
with a p-value of ≤ 0.05. The probe sets with "absence"
call on the array were removed before normalization. A
total of 852 genes showed differential expression between
HCC and ANC samples (Table 2 and Additional file 1).
The up-regulated 515 genes and down-regulated 337
genes from the FDR-corrected data covered 41% and 72%
of the up- and down-regulated genes, respectively, listed
in the data generated by Welch's T-test with Bonferroni
correction and p ≤ 0.001[13]. As reported previously,
genes for DNA synthesis, cell cycle and ubiquitination,
including RRM2, CCNB1, AURKA, NUSAP1, UBE2S,
UBE2T, etc. were over-expressed; whereas genes for cell
death and liver function, such as Egr1, MT1F and p450
family members, were under-expressed in HCC relative to
the ANC tissue.
JNK1 activation in HCC
We had previously shown activation of JNK1 in about
55% of human HCC samples as compared with the case-
matched ANC samples through immunoblotting[13]. To
validate these observations again, we also examined JNK
activation status in some additional HCC tissue samples
paired with ANC tissue in tissue microarray through
immunohistochemistry (IHC) analysis (Fig. 1). Since an
antibody specific for phosphorylated-JNK1 (pJNK1) was
Table 1: Clinical information for the H-JNK1 and L-JNK1 HCC 
patients
H-JNK1
n = 17
L-JNK1
n = 14
p – value
Sex (M/F) 13/4 10/4 0.5616
Age, y (range) 55.6 (32–70) 52.3 (42–69) 0.4110
HBV 13 9 0.4903
HCV nd* nd
C i r r h o s i s 590 . 1 9 3 6
Encapsulation 5 9 0.1936
AFP (+/-) 12/5 9/5 0.5486
>  2 0 0 950 . 3 9 7 1
>  4 0 0 830 . 2 5 0 7
Tumor grade (II/III) 7/10 9/5 0.3401
Tumor diameter (cm) 7.3 ± 2.8 5.0 ± 2.7 0.0270
Survival (months) 21.7 ± 19** 39.1 ± 30 0.073
Male 14 ± 14 42 ± 30 0.0120
Female 43 ± 14 28 ± 34 0.459
*nd: not determined
**data for 2 out of 31 patients were not available due to loss of 
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unavailable, we used an antibody against both pJNK1 and
pJNK2. Despite the fact that both HCC and ANC exhib-
ited a similar weak background signal in IHC, possibly
due to pJNK2 as demonstrated in our previous Western-
blotting[13], 24 out of 52 HCC samples (46%) in the tis-
sue microarray slides showed a notable enhancement of
pJNK signal as compared with the ANC tissue (represent-
ative images in Fig. 1A). Of note, the enhancement of JNK
activation as implicated in the phosphorylation of the
JNK largely occurred in the nuclei of the hepatocytes (top
panels in Fig. 1A) and was not uniformly distributed in
the whole HCC tissue in the majority of tissue slides, but
rather, clustered in certain limited areas, especially in
those areas featured with small foci of necrosis (Fig. 1B).
The JNK1 activation was further validated by a JNK1 spe-
cific kinase activity assay in additional 4 HCC samples
paired with the ANC tissues (Fig. 1C).
JNK1-associated HCC signature genes
Based on the JNK1 activation status in HCC relative to the
ANC tissue, we further classified gene expression profiles
associated with H-JNK1 HCC and L-JNK1 HCC, respec-
tively. To gain strong biological and statistical signifi-
cance, the genes with a larger than 5-fold differential ratio
between HCC and ANC samples were selected for further
analysis. A list of 1,828 genes was generated for the H-
JNK1 HCC, among which 707 genes were up-regulated
and 1,121 genes were down-regulated (Additional file 2).
In L-JNK1 HCC samples, 164 genes were up-regulated and
411 genes were down-regulated (Additional file 3). The
lower JNK1 activity in this group of HCC samples was
supported by the down-regulation of the Jun, Fos and Myc
signaling pathways in an interactive network analysis
(Figs. 2A, B &2C). By comparing the up- and down-regu-
lated genes in these two groups, only 28 genes were com-
monly up-regulated (Fig. 2D and Additional file 4) and
124 genes were commonly down-regulated between them
(Fig. 2D and Additional file 5). Furthermore, 12 up-regu-
lated genes in H-JNK1 HCC samples were down-regulated
in the L-JNK1 HCC samples (Fig. 2D and Additional file
6) and 10 down-regulated genes in the H-JNK1 HCC sam-
ples were up-regulated in the L-JNK1 HCC samples (Fig.
2D and Additional file 6). Accordingly, the vast majority
of the genes identified are truly associated with the JNK1
activation status in HCC samples.
To determine potential signature genes defining the H-
JNK1 and L-JNK1 HCC tissue, a new gene list was gener-
ated by direct comparing the genes in H-JNK1 HCC to the
L-JNK1 HCC samples. This comparison showed that 927
genes were over-expressed and 1,057 genes were under-
expressed in H-JNK1 HCC samples relative to the L-JNK1
HCC samples with a differential ratio large than 5 fold
(Additional file 7). The 30 most up-regulated and the 30
most down-regulated genes in H-JNK1 HCC tissue are
shown in Fig. 3A. Some of the top 30 genes are associated
with the liver progenitor cells and the imprinted genes,
such as PEG10, CD24, H19, and KRT19. Several genes
representing the normal liver function, such as CYP family
members, NAT2, ADH1B, and ADH4, are among the 30
most down-regulated genes. The relative expression levels
of PEG10, CD24, IER3, IGFBP3, HPD and FMO3 in H-
Table 2: The 10 most up- and down-regulated genes in HCC tissue vs ANC tissue
Probe ID Fold FDR Gene Description
209773_s_at 42.92361 0.049469 RRM2 ribonucleotide reductase M2
214710_s_at 31.22006 0.045816 CCNB1 cyclin B1
208079_s_at 22.2925 0.045693 AURKA aurora kinase A
218039_at 14.23746 0.045693 NUSAP1 nucleolar/spindle protein 1
202779_s_at 14.00133 0.045816 UBE2S ubiquitin-conjugating E2S
225687_at 13.5030 0.036302 FAM83D family with similarity 83 D
218883_s_at 13.12003 0.046408 MLF1IP MLF1 interacting protein
219787_s_at 12.05556 0.049035 ECT2 epithelial transforming 2
209218_at 11.85705 0.048765 SQLE squalene epoxidase
223229_at 11.59042 0.045816 UBE2T ubiquitin-conjugating E2T
223699_at -52.7765 0.028925 CNDP1 carnosine dipeptidase 1
202992_at -54.1709 0.033434 C7 complement component 7
206727_at -59.2 0.045816 C9 complement component 9
207102_at -61.2122 0.048508 AKR1D1 aldo-keto reductase 1D1
230478_at -73.8474 0.02547 OIT3 oncoprotein induced transcript 3
205866_at -75.0982 0.014497 FCN3 ficolin 3
206354_at -96.8498 0.028696 SLCO1B3 solute carrier organic transporter
220491_at -97.3833 0.028696 HAMP hepcidin antimicrobial peptide
1554459_s_at -98.797 0.045816 CFHR3 complement factor H-related 3
207874_s_at -112.08 0.046995 CFHR4 complement factor H-related 4Molecular Cancer 2009, 8:64 http://www.molecular-cancer.com/content/8/1/64
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JNK1 and L-JNK1 HCC tissue are shown in Fig. 3B. It
should be noted that although both H-JNK1 and L-JNK1
HCCs samples showed decreased expression of IGFBP3
relative to the matched ANC samples as reported by oth-
ers[20], the IGFBP3 level in L-JNK1 HCC tissue is much
lower than that in H-JNK1 HCC tissue (Fig. 3B). The dif-
ferential expression levels of some of these genes between
H-JNK1 and L-JNK1 HCC were additionally validated by
quantitative real-time PCR (Fig. 4A).
An additional functional comparison between these two
groups indicates that the expression of the genes for
amino acid metabolism, small molecule biochemistry,
cell cycle, and DNA replication was overexpressed in the
H-JNK1 HCC tissue relative to the L-JNK1 HCC tissue
(Fig. 4B). In contrast, the genes for cell-to-cell interaction,
cell signaling, cell morphology, and free radical scaveng-
ing were up-regulated in the L-JNK1 HCC tissue relative to
the H-JNK1 HCC tissue (Fig. 4B).
Biological networks in H-JNK1 HCC vs L-JNK1 HCC
To gain insights into the JNK1 activation and HCC patho-
genesis, we carried out additional interactive gene net-
work analysis using the Ingenuity Pathways Analysis
software for those differentially regulated genes between
H-JNK1 and L-JNK1 HCC samples with a ratio larger than
5 fold. Among the 927 up-regulated genes in H-JNK1
HCC samples relative to the L-JNK1 HCC samples, many
genes can be mapped to the top five interaction networks
for cell growth, cell cycle, cell death, cellular assembly,
and DNA replication (Fig. 5A and Additional file 8).
Intriguingly, HIF1A and many of its targeting molecules
were also up-regulated, further supporting the highly pro-
liferative nature of the H-JNK1 HCC tissue (Fig. 5B). The
top interactive networks for the down-regulated genes in
the H-JNK1 HCC samples relative to the L-JNK1 HCC
samples are those involved in hepatic transcription factor
HNF4A network and metabolisms for lipids and drugs,
such as the p450 family members (Figs. 5C and 5D; Addi-
tional file 8).
Activation of JNK is enhanced in HCC samples Figure 1
Activation of JNK is enhanced in HCC samples. (A). Tissue microarray with paired human HCC and the adjacent non-
cancerous tissue (ANC) was stained with pJNK antibody. The inserted panels show a typical immunostaining pattern of pJNK 
in a single HCC cell and non-cancerous cell, respectively; (B). Enhanced pJNK staining in the small foci of necrosis was indicated 
by the red arrows in HCC tissue. (C). JNK1 specific kinase activity assay in 4 HCC tissue samples (T) paired with the non-can-
cerous liver tissues (N).
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The Jun, Fos and Myc signaling pathways were down-regulated in the low JNK1 (L-JNK1) HCC tissue Figure 2
The Jun, Fos and Myc signaling pathways were down-regulated in the low JNK1 (L-JNK1) HCC tissue. Genes 
associated with the Jun signaling (A), Fos signaling (B) and Myc (C) signaling pathways were down-regulated in L-JNK1 HCC tis-
sue. (D) Cross-coverage of the genes between H-JNK1 and L-JNK1 HCC samples were measured by Venn Diagrams.Molecular Cancer 2009, 8:64 http://www.molecular-cancer.com/content/8/1/64
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Overlapping of the signature genes between H-JNK1 HCC 
tissue and HCC with poor prognosis
A number of previous studies reported potential HCC sig-
nature genes associated with metastasis, recurrence and
patient survival [9,21-24]. To determine whether there is
a concordance between the JNK1-related gene profiling
and those previously reported HCC signature genes, we
compared our data with some of these earlier reports. To
simplify such comparison, we arbitrarily selected the 30
most up-regulated and the 30 most down-regulated genes,
as indicated in Fig. 3A, in the H-JNK1 HCC tissue as com-
pared with the L-JNK1 HCC tissue. Among the top 30
genes overexpressed in the H-JNK1 HCC tissue relative to
the L-JNK1 HCC tissue, 23 genes had been previously
implicated as signature genes either for HCC itself or for
the prediction of poorer prognostic outcomes, such as
impaired patient survival, intra-hepatic or extra-hepatic
metastasis, and earlier recurrence of the tumor after surgi-
cal resection. These overlapping HCC signature genes
include S100P [12], S100A8 [22], S100A9 [12], CCL20
[11,25], PEG10 [16], CD24 [11,16,26], NTS [9],
SPP1[24], PLAC8 [27], H19 [28,29], SPINK1 [30],
GALNT7 [11] HMGA2 [16], C1orf106 [12],
AMIGO2[11,23], AFP [11,22], UBE2C [11,31],
SOX4[11,16,32], IER3 [9], TMED3 [12], IGFBP3 [33],
S100A4 [34], and KRT19 [22] (Table 3).
Fifteen out of the 30 most down-regulated genes in the H-
JNK1 HCC tissue were covered by those down-regulated
genes in the subclass A HCC reported by Lee et al[9]. The
subclass A HCC had been later confirmed as the HCCs
derived from the hepatic progenitor cells with poorer sur-
Signature genes of the H-JNK1 HCC samples Figure 3
Signature genes of the H-JNK1 HCC samples. (A). The 30 most up-regulated and the 30 most down-regulated genes 
were generated from direct comparison of the gene profiling between H-JNK1 HCCs and L-JNK1 HCC samples. (B). Relative 
expression levels of PEG10, CD24, IER3, IGFBP3, HPD, and FMO3 in H-JNK1 HCC and L-JNK1 HCC samples.
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vival[22]. These genes include HPD, CYP3A4, SERPINC1,
AQP9, GLYAT, OTC, PCK1, CYP2E1, CYP2C9, CYP8B1,
FMO3, BAAT, SLC27A5, SLC22A1, and CYP2D6 (Table
3). In addition, 9 genes, including GYS2 [11], F9 [12,35],
NAT2 [11,36,37], ADH1B [26], LECT2 [11,38,39], AFM
[11], ADH4 [11,21], SLC10A1 [40], and HSD11B1 [11],
in this down-regulated gene list that were not covered in
the down-regulated genes of Lee et al.[9], had been
recently or previously reported to be substantially
decreased in HCC with poorer prognosis.
H-JNK1 HCC with features of liver progenitor cells and 
hepatoblastoma (HB)
The similarity between HCCs with higher JNK1 activation
and the HCCs with characteristics of hepatic progenitor
cells (Fig. 3A) suggests to us that the H-JNK1 HCCs possi-
bly have features of HB. The signature genes for HB has
been recently reported by Cairo et al [16]. By comparing
the signature genes of HB with that of H-JNK1 HCC tissue,
a striking similarity between the genes in robust Cluster 2
(rC2) HB and the genes associated with the JNK1 activa-
tion status was noted. For the top 400 increased and great-
est 100 decreased genes in rC2 HB (Supplemantary table
S7 of Cairo et al [16]), 90% and 94% of these genes are
presented among the most increased and decreased
expressed genes in the H-JNK1 HCC tissue, respectively.
Vice versa, 11 out of the 30 most up-regulated genes and
20 out of the 30 most down-regulated genes in the H-
JNK1 HCC tissue are represented by the up- and down-
regulated genes in the HB or rC2 HB, respectively (Table
3). A significant agreement of the 16 signature genes dif-
ferentiating rC2 and rC1 HB (see Cairo et al [16]) and the
signature genes for the H-JNK1 HCC tissue was evident.
The listed up- and down-regulated 16 signature genes in
rC2 HB are fully overlap with the up- and down-regulated
genes in H-JNK1 HCCs (Additional file 9).
We also noted that similar to the rC2 HB, several liver pro-
genitor markers, such as AFP [16], TACSTD1 [41], KRT19
[16,22], KRT7 [22], PROM1 (CD133) [41,42], THY1
(CD90) [42] and VIM [22], are significantly up-regulated
in the H-JNK1 HCC samples relative to the L-JNK1 HCC
samples (Additional file 10). A characteristic feature of the
HB and hepatic progenitor cells is the enhanced expres-
sion of the imprinted genes, including H19, IGF2, DLK1,
PEG3, PEG10, MEG3, SGCE, and NDN [16]. Indeed, all of
these mentioned imprinted genes are up-regulated in the
H-JNK1 HCC samples (Additional file 10).
Compromised survival of the patients with H-JNK1 HCCs
Both HB-type HCC and rC2 HB patients exhibited poorer
survival relative to HC-type HCC and rC1 HB patients
[16,22]. Because of the overall similarity in the gene
expression profiling between the H-JNK1 HCC samples
and HB or HB-type HCCs (Table 3), we thought that the
status of JNK1 activation in HCC samples might be able
to predict the prognostic outcome, especially on the
patient survival. The patient survival data were collected
during the follow-up monitoring after surgical resection
of the tumor. Among the 31 patients, the survival data of
2 patients were not available due to living in an area
beyond the surveillance radius and undisclosed details of
Comparison of genes and pathways between H- and L-JNK1 HCCs through real-time PCR and pathway assay Figure 4
Comparison of genes and pathways between H- and L-JNK1 HCCs through real-time PCR and pathway assay. 
(A). Quantitative real-time PCR of the selected genes showing differential expression between H- and L-JNK1 HCC. (B). Dif-
ferent expression levels of the genes associated with these indicated interactive pathways were determined by comparing path-
way molecules between H-JNK1 HCC and L-JNK1 HCC samples through Ingenuity Pathways Analysis.
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home address. The remaining 29 patients were sub-
grouped according to the JNK1 activation status in their
tumors. The average survival of the patients with H-JNK1
HCC and L-JNK1 HCC were 21.7 and 39.1 months,
respectively (Fig. 6A). However, such difference did not
reach statistical significance. Since we noted a substantial
difference in survival in male and female patients with H-
JNK1 HCC (Table 1 and Fig. 6B), we assumed that the H-
JNK1 HCC might impose stronger effect on survival for
male patients. Thus, we excluded the survival data for the
7 female patients and analyzed the survival data again.
The average survival of the male patients with H-JNK1
HCC is 14 months, which is significantly shorter than
41.5 months on average for the patients with L-JNK1 HCC
(Fig. 6C). A Kaplan-Meier estimation of the overall sur-
vival probability at one year was 91% for patients with L-
JNK1 HCC and 18% for patients with H-JNK1 HCC (Fig.
6D). Accordingly, these data suggest that the patient sur-
vival was severely impaired in H-JNK1 HCC, especially for
male patients.
Discussion
HCC is a heterogeneous type of tumor despite overall out-
comes of poor prognosis. Depending on etiological and
the accompanying pathological conditions, the survival
or tumor recurrence vary considerably among HCC
patients. The cellular origin of HCC may play key roles in
determining the status of metastasis, intra-hepatic recur-
Major signaling pathways were altered in H-JNK1 HCC tissue Figure 5
Major signaling pathways were altered in H-JNK1 HCC tissue. Genes for cell cycle pathway (A) and HIF-1 signaling (B) 
were up-regulated in H-JNK1 HCC tissue as determined by Ingenuity Pathways Analysis. Genes involved in HNF4A transcrip-
tion network (C) and for the p450 family members (D) were down-regulated in H-JNK1 HCC tissue.
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rence and patient survival. It has been debated for decades
whether HCC arises exclusively by dedifferentiation of
mature hepatocytes or maturation arrest of liver stem cells
or progenitor cells (oval cells in rodents). Great efforts
have been made in identifying bipotential hepatic progen-
itor cells that can differentiate into hepatocytes and
cholangiocytes [43]. Markers for hepatocytes, such as AFP
and albumin, and cholangiocytes, mainly KRT7 and
KRT19, are expressed in the progenitor cells. Evidence
supporting progenitor cell origin of HCC is largely based
on the fact that many HCCs concurrently express both
hepatocytic markers and cholangiocytic markers along
with stem cell markers including TACSTD1 (EpCAM),
PROM1 (CD133) and THY1 (CD90) [41,42]. The obser-
vation that a profound concordance of gene profiles for
H-JNK1 HCC tissue with those of Lee et al.[22] on HB-
type HCC tissue and Cairo et al. [16] on HB samples may
support the hypothesis that H-JNK1 HCC is derived from
the liver progenitor cells. Indeed, the genes for KRT7,
KRT19, PROM1, AFP, as well as imprint genes are overex-
pressed in the H-JNK1 HCC tissue (Additional file 10).
The HB-like features of the H-JNK1 HCC tissue are addi-
tionally supported by the recent characterization of the
EpCAM positive cells in human HCC samples. By classify-
ing 235 HCC tumor specimens with gene profiling and
immunohistochemistry analyses, Yamashita et al.[12]
reported signature genes that were differentially expressed
between EpCAM positive, stem cell-like HCC (HpSC-
HCC) and the EpCAM negative mature hepatocyte-like
HCC. A number of genes are commonly over-expressed
between H-JNK1 HCC and the HpSC-HCC, such as
S100P, S100A9, CCL20, PEG10, CD24, NTS, H19,
UBE2C, TMED3, and KRT19 that were listed among the
30 most up-regulated genes in H-JNK1 HCC tissue (Table
3). Majority of the 30 most down-regulated genes, 22
genes, were also under-expressed in HpSC-HCC tissue.
Interestingly, both H-JNK1 HCC and HpSC-HCC samples
Table 3: Overlapping of H-JNK1 signature genes with other types of HCCs
Up in
H-JNK/L-JNK
HB
HCC§
Up In HB** mTOR
HCC¶
EpCAM
HCC†
Down in
H-JNK1/L-JNK1
HB
HCC
Down
In HB
mTOR
HCC
EpCAM
HCC
Genes Fold rC2/rC1* Genes Fold rC2/rC1
S100P 611 Y CYP2D6 -112 Y 0.1 Y
S100A8 371 Y a Y GYS2 -122 0.1 Y Y
AGR2 309 F9 -141 0.1 Y
S100A9 278 a Y CFHR5 -148 Y
CCL20 266 Y Y NAT2 -151 0.2 Y
PEG10 206 14.9 Y ADH1B -151 0.1
CD24 163 6.7 Y Y SPP2 -154 a
NTS 143 Y Y LECT2 -155 Y Y
SPP1 126 Y SLC22A1 -156 Y 0.1 Y
PLAC8 121 a Y SLC27A5 -156 0.2 Y
H19 92 qPCR Y BAAT -173 Y Y
SPINK1 78 Y FMO3 -183 Y 0.1 Y Y
GALNT7 63 Y RTP3 -217 Y
HMGA2 61 5.5 Y ACSM2B -222 Y
C1orf106 61 Y CYP8B1 -224 Y Y Y
AMIGO2 55 Y AFM -239 a Y
AFP 54 35 Y CYP2C9 -242 Y 0.2 Y
XIST 52 CYP2E1 -244 Y 0.2 Y
UBE2C 51 Y PCK1 -251 Y 0.1 Y
NEBL 49 OTC -276 Y Y
SOX4 48 3.0 Y HSD17B6 -298 0.1 Y
IER3 45 Y Y GLYAT -458 Y 0.2 Y Y
EGLN3 42 CYP2C8 -525 0.0 Y
TMED3 40 Y ADH4 -535 Y
PRKAR2B 40 Y AQP9 -684 Y 0.2 Y Y
IGFBP3 39 Y SERPINC1 -711 Y a Y
S100A4 39 Y SLC10A1 -975 0.1 Y
BASP1 38 b HSD11B1 -1040 0.1 Y Y
CXCL13 37 CYP3A4 -1458 Y
KRT19 34 Y 10.5 Y HPD -1864 Y 0.2 Y
A: Up or down in later stage HB; b: Up or down in early stage HB; *: ratio of rC2/rC1; Y: covered by the indicated studies; §HB HCC, ref.[22]; 
**HB: ref. [16]; ¶mTOR HCC: ref. [11]; †EpCAM HCC: ref. [12].Molecular Cancer 2009, 8:64 http://www.molecular-cancer.com/content/8/1/64
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The survival of the patients with H-JNK1 HCC was compromised Figure 6
The survival of the patients with H-JNK1 HCC was compromised. (A). Average survival (months) of the patients 
(male and female) with H-JNK1 and L-JNK1 HCCs; (B). Sex discrepancy of the patients with H-JNK1 HCC. Male patients with 
H-JNK1 HCC have a significant shorter survival times than the female patients with H-JNK1 HCC; (C). The survival time of the 
male patients with H-JNK1 HCC is significantly shorter than the male patients with L-JNK1 HCC; (D). Survival probability of 
the male patients with H-JNK1 and L-JNK1 HCC was determined by a Kaplan-Meier estimation.
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showed poorer prognosis in a Kaplan-Meier survival anal-
ysis.
Most recently, Villanueva et al.[11] reported signature
genes for HCC samples with an aberrant mTOR signaling.
About 40% of the 193 up-regulated genes in this type of
HCC were found in the up-regulated gene list for H-JNK1
HCC samples. The coverage was increased to 86% if one
relaxed the 5-fold cutoff to 1.5 fold and removed those
uncharacterized genes (data not shown). For the down-
regulated genes, more than 91% of the known genes were
represented in the list of the down-regulated genes in H-
JNK1 HCC samples. Vice versa, the genes for CCL20,
CD24, GALNT7, AMIGO2, AFP, UBE2C, and SOX4 in the
30 most up-regulated genes in the H-JNK1 HCC samples
were represented in the HCC samples with an aberrant
activation of mTOR signaling (Table 3). The similarity in
gene expression pattern between H-JNK1 HCC and the
HCC with abnormal mTOR signaling further supports the
assumption that H-JNK1 HCCs are the tumors with a
highly aggressive nature and poorer prognosis.
It is worth to mention that there appears to be a gender
disparity in JNK1 activation and HCC survival probability
between male and female patients (Fig. 6B). A strong cor-
relation between higher JNK1 activation and lower sur-
vival probability was noted in male, but not in female
patients. Such disparity may be possibly attributed to the
different levels of the sex steroids between two genders. It
has long been hypothesized that certain female sex hor-
mone, esp. estrogen, is repressive for the expression of
inflammatory genes, such as IL-6, leading to tumor sup-
pression [44]. In contrast, male sex hormone, androgen,
appears to be a promoting factor for HCC [45]. It is
unclear at the present whether the higher JNK1 activity or
its down-stream effect in the female HCC patients is
antagonized by the sex hormone. Nevertheless, the
observed disparity in JNK1 activation and HCC prognosis
between male and female patients is compensatory to the
human epidemiological and animal tumorigenic studies
demonstrating that the HCC incidence rate in male is
about 3–5 times higher than that in female [8,45].
Conclusion
In summary, we believe that the present report not only
provides evidence indicating that JNK1 activation contrib-
utes to poorer HCC prognosis but also aids in molecular
classification for HCC. It is conceivable that HCC samples
with high JNK1 activation possess feature of hepatic pro-
genitor cells and have similarities with HB[16], HB-type
HCC[22], mTOR-altered HCC[11], and the EpCAM+/
AFP+ HCC (HpSC-HCC)[41]. In addition to this notion,
complementary evidence to support JNK1 activation in a
subset of HCC tissue was previously provided by Lee et
al.[22] who demonstrated a strong enrichment of the AP-
1 signaling, a direct down-stream target of JNK1, in HB-
type HCC samples. The final goal of cancer gene profiling
is to design targeted therapy and/or so-called personalized
medicine. However, such goal is hard to achieve currently
due to the large quantity of the cancer signature genes and
the lack of a clear picture of the drug targetable genes or
gene networks. The activation of the major signaling path-
ways, such as JNK1 and mTOR, on the other hand, is
potentially targetable by relatively specific therapeutic
agents. Thus, the identification of H-JNK1 HCC opens up
possibilities to develop new treatment strategies targeting
the intercellular signaling to delay the progression of
HCC.
Methods
Human hepatocellular carcinoma specimens
The human HCC tissue samples were collected from
patients undergoing surgical resection procedures with
informed consent from the patients according to a proto-
col approved by the Institutional Review Board at Qidong
Liver Cancer Institute, Qidong, PR China. Partial adjacent
noncancerous (ANC) liver tissue with an average distance
of 1.28 cm from the tumor were also collected for patho-
logical evaluation. The tissue specimens were stored in
liquid nitrogen immediately for later pathological and
biological analyses. The diagnostic, clinical and patholog-
ical stages of the tumors were determined as previously
reported[13]. Clinical relevant information for the HCC
patients is shown in Table 1. A total of 40 HCC samples
along with 40 case-matched ANC liver tissues were col-
lected, among which 31 HCC samples and the matched
ANC tissue were used in the present study. The other 9
HCC samples were excluded from this study because of
combined cholangiocarcinoma or other type of tumors.
For immunohistochemistry (IHC) studies, tissue microar-
ray slides containing total of 52 HCC samples were pur-
chased from US Biomax, Inc., (Rockville, MD), (See
following).
Western blotting, JNK1 kinase activity assay and 
Immunohistochemistry (IHC)
The JNK activation in both HCC tissues and non-cancer-
ous liver tissues was determined through Western blotting
using antibodies against phospho-JNK and total JNK pur-
chased from Cell Signaling (Beverly, MA) as described
previously[13]. JNK1 specific kinase activity assay was per-
formed through immunoprecipitation using JNK1 anti-
body purchased from Santa Cruz Biotechnology Inc. (sc-
474, Santa Cruz, CA) and the JNK kinase activity assay kit
provided by Cell Signaling Technology (Beverly, MA). Tis-
sue microarray slides (LV241 and LV801) purchased from
US Biomax, Inc. (Rockville, MD) were used for IHC.
LV241 and LV801 slides contained 12 and 40 HCC speci-
mens along with the case-matched ANC tissue, respec-
tively. The information about the histopathological andMolecular Cancer 2009, 8:64 http://www.molecular-cancer.com/content/8/1/64
Page 12 of 14
(page number not for citation purposes)
patient data is available at the manufacturer's website
http://www.biomax.us/tissue-arrays/. The tissue slides
were baked at 60°C for 30 min and then deparaffinized
by xylene before IHC. For IHC, the slides were first sub-
jected to antigen retrieval and then incubated with normal
goat serum for 20 min at room temperature, followed by
incubation with anti-phospho-JNK antibody (1:50 dilu-
tion). Other procedures of IHC were applied as suggested
by the manufacturer. Specific antibodies for JNK1, JNK2
and phosphorylated-JNK were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA) or Cell Signaling Tech-
nology (Beverly, MA).
Microarray and interactive pathway analyses
Gene expression profiling was performed according to the
protocols described by Affymetrix, Inc. (Santa Clara, CA).
Raw data from Affymetrix HG-U133 plus 2.0 Gene Chip
microarray were normalized using the GeneChip Robust
Multiarray Averaging (GCRMA) method and by removing
probe sets with "absence" call on the array. The data were
further calibrated by False Discovery Rate (FDR) correc-
tion with a p-value ≤ 0.05. The gene profiling data were
further sub-grouped according to the JNK1 activation sta-
tus in the HCC tissue relative to the ANC tissue to generate
gene lists for both the high JNK1 (H-JNK1) HCC tissue
and low JNK1 (L-JNK1) HCC tissue. A list of genes with a
larger than 5-fold differential expression between H-JNK1
HCC and L-JNK1 HCC was also made based on direct
comparison between these two groups. An online trial
version of Ingenuity Pathways Analysis was used for the
interactive network assay. For each gene list, independent
analyses for all genes, over-expressed genes, and under-
expressed genes were performed. The significance of each
network was estimated as described by Lee et al.[22].
Quantitative real-time PCR
Primers were designed using the universal probe library
from Roche Applied Science (Applied Biosystems). Primer
sequences and probe numbers are available upon request.
Gene expression levels were analyzed by quantitative PCR
in an ABI-PRISM®  7900 sequence detection system
(Applied Biosystems) and normalized to GAPDH. Sam-
ples were run in triplicate under quantitative PCR condi-
tions. Data were quantified and normalized using the ΔCt
method. Cycling conditions PCR were 2 min at 50°C, 10
min at 95°C, then 40 cycles of 15 s at 95°C, and 1 min at
60°C.
Analysis of patient survival data and statistics
Patient survival data were collected through the Qidong
Cancer Registration System, a comprehensive cancer sur-
veillance program, and follow-up monitoring of the
patients after tumor resection. Patient survival time in
months was calculated from the date of the first diagnosis
of the tumor to the date of patient death. For the patients
who were alive at the time of final data collection on Sep-
tember 30, 2008, the survival time was determined from
the date of the first diagnosis to September 30, 2008. The
Kaplan-Meier method was used to determine the survival
probability of the patients with H-JNK1 HCC or L-JNK1
HCC. SigmaPlot 9.0 statistics software or Fisher's Exact
Test was used to analyze statistic significance or clinical
features.
Raw data of microarray can be found from: http://
sites.google.com/site/cancerepigeneticsandsignaling/
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